TerminatedPhase 3NCT00089804
Study of LJP 394 in Lupus Patients With History of Renal Disease
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- La Jolla Pharmaceutical Company
- Principal Investigator
- Michael J Tansey, MD, Ph.D.Chief Medical Officer, La Jolla Pharmaceutical Company
- Intervention
- abetimus sodium (LJP 394) and/or placebo solution(drug)
- Enrollment
- 943 enrolled
- Eligibility
- 12-70 years · All sexes
- Timeline
- 2004 – 2009
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Wallace Rheumatic Study Center, Los Angeles, California, United States
- East Bay Rheumatology Medical Group, San Leandro, California, United States
- Private Practice, San Mateo, California, United States
- CRIA Research, Fort Lauderdale, Florida, United States
- Miami Children's Hospital, Miami, Florida, United States
- Emory University School of Medicine, Renal Division, Atlanta, Georgia, United States
- Private Practice, Augusta, Georgia, United States
- Southeast Regional Research Group, Savannah, Georgia, United States
- Intermountain Orthopedics, Boise, Idaho, United States
- Rheumatology Associates, Chicago, Illinois, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- SOMARC Trials, LLC, Greenbelt, Maryland, United States
- Nephrology Associates, PC, Flushing, New York, United States
- North Shore - LIJ Health System, Lake Success, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00089804 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology